Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals

REFERENCES

• Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175–2185.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186–2195.
   PubMed Web of Science ®Google Scholar
• Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovi-rals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005;40:413–421.
   PubMed Web of Science ®Google Scholar
• Reynes J,Arasteh K,Clotet B,etal.TORO: ninety-six-week virologic and immunologic response and safety evalua-tion of enfuvirtide with an optimized background of anti-retrovi rals. AIDS Patient Care STDS. 2007;21:533–543.
   PubMed Web of Science ®Google Scholar
• Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404–412.
   PubMed Web of Science ®Google Scholar
• Battegay M, DeMasi R, Delehanty J, Chung J, Huson L, Salgo M, on behalf of the TORO 1 and TORO 2 study group. Analysis of virological failure through 24 weeks of treatment in the TORO pivotal studies. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; 2003; Paris.
   Google Scholar
• Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466–475.
   PubMed Web of Science ®Google Scholar
• Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med. 2007;8:259–264.
   PubMed Web of Science ®Google Scholar
• Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169–1178.
   PubMed Web of Science ®Google Scholar
• Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395–402.
   PubMed Web of Science ®Google Scholar
• Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treat-ment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007;46:24–31.
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infec-tion. N Engl J Med. 2008;359:355–365.
   PubMed Web of Science ®Google Scholar
• Loutfy MR, Antoniou T, Shen S, et al. Virologic and immu-nologic impact and durability of enfuvirtide-based anti-retroviral therapy in HIV-infected treatment-experienced patients in a clinical setting. HIV Clin Trials. 2007;8: 36–44.
   PubMed Web of Science ®Google Scholar
• The Swiss HIV Cohort Study. Available at: http://www.shcs.ch.
   Google Scholar
• Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded sur-veillance case definition for AIDS among adolescents and adults. MMWR. 1992;41(no. RR–17).
   Google Scholar
• World Health Organization. The International Classification of Diseases and Related Health Problems, 10th revision (ICD-10). Available at: http://www.who.int/classifications/apps/icd/icd1Oonline/.
   Google Scholar
• Raffi F, Katlama C, Saag M, Wilkinson M, Chung J, Smiley L, Salgo M. Week-12 response to therapy as a predictor of week 24,48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Reg-imen Only (TORO) trials. Clin Infect Dis. 2006;42: 870–877.
   PubMed Web of Science ®Google Scholar
• Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis. 2006;43:1337–1346.
   PubMed Web of Science ®Google Scholar
• May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185–1197.
   PubMed Web of Science ®Google Scholar
• Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679–686.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220–2226.
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral ther-apy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129.
   PubMed Web of Science ®Google Scholar
• Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS. 2008:22:1224–1226.
   PubMed Web of Science ®Google Scholar
• Salzberger B, Daumer M, Gute P, et al. Consensus recom-mendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients. Eur J Med Res. 2007;12:93–102.
   PubMed Web of Science ®Google Scholar
• Rachlis A, Angel J, Harris M, et al. Canadian consen-sus recommendations for the optimal use of enfuvirtide in HIV/AIDS patients. Can J Infect Dis Med Microbiol. 2006;17:155–163.
   PubMedGoogle Scholar
• Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS. 2004;18:1137–1146.
   PubMed Web of Science ®Google Scholar